Stocks › Infectious Disease › MRNA

Moderna MRNA

US equityMarket cap rank #227Infectious Disease

$183.47

+$1.36 (+0.75%)

Market open · Sep 24, 1:10 pm ET

After hours $181.30 -0.44%

Open$180.60

Prev close$182.11

Day range$180.39 – $189.22

Volume8.01M

Market cap$73.25B

P/E (TTM)–

Dividend yield–

Beta Pharma (300558.SZ): Currently has no relevant layout in the mRNA field. Gelonghui Finance · 9 Sep 2026
HK Stock Market Alert | Jitai Technology-P (07666) surges over 20% in afternoon session; cumulative gain exceeds 30% in two days of inclusion in the Stock Connect. Global AI + mRNA vaccine sector accelerates. Zhitong Finance · 8 Sep 2026
Hualan Biological Engineering Inc. (002007.SZ): Controlled subsidiary receives approval notice for clinical trials of novel influenza mRNA vaccine Gelonghui Finance · 7 Sep 2026
Nano Holdings: New research findings on mRNA therapeutics have been announced by the group led by Professor Akihisa Iitaka. JPX · 4 Sep 2026
DBS Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $150 Market news · 12 Sep 2026
Form 144 | Moderna(MRNA.US) Officer Proposes to Sell 4.69 Million in Common Stocks Market news · 10 Sep 2026
CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - SYS6037 INJECTION (MPOX MRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. HKEX · 10 Aug 2026
Nano Holdings: Statutory Post-Disclosure Documents (Corporate Split) (NANO MRNA Co., Ltd.) JPX · 24 Apr 2026
Nano Holdings: Notice Regarding the Transfer of a Subsidiary Resulting from NANO MRNA, a Strategic Subsidiary, Acquiring Shares in Luna RD Co., Ltd. (Making It a Wholly Owned Subsidiary) JPX · 24 Apr 2026
Nano Holdings: (Correction) Regarding a Partial Correction to the "Notice on Changes in Subsidiaries Resulting from Luna RD Co., Ltd.'s Acquisition of Shares in Luna RD Co., Ltd. by Strategic Subsidiary NANO MRNA (Subsidiarization)" JPX · 24 Apr 2026